Biocomposite for Prolonged Release of Water-Soluble Drugs
Metadata
Show full item recordEditorial
MDPI
Materia
Chitosan Palygorskite Composite Drug delivery Prolonged release
Date
2023-06-14Referencia bibliográfica
Meirelles, L.M.A.; de Melo Barbosa, R.; de Almeida Júnior, R.F.; Machado, P.R.L.; Perioli, L.; Viseras, C.; Raffin, F.N. Biocomposite for Prolonged Release ofWater-Soluble Drugs. Pharmaceutics 2023, 15, 1722. [https://doi.org/10.3390/pharmaceutics15061722]
Sponsorship
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brazil (CAPES)—Process n 88887.131333/2016-00.Abstract
This study aimed to develop a prolonged-release system based on palygorskite and chitosan,
which are natural ingredients widely available, affordable, and accessible. The chosen model drug
was ethambutol (ETB), a tuberculostatic drug with high aqueous solubility and hygroscopicity, which
is incompatible with other drugs used in tuberculosis therapy. The composites loaded with ETB were
obtained using different proportions of palygorskite and chitosan through the spray drying technique.
The main physicochemical properties of the microparticles were determined using XRD, FTIR, thermal
analysis, and SEM. Additionally, the release profile and biocompatibility of the microparticles were
evaluated. As a result, the chitosan–palygorskite composites loaded with the model drug appeared
as spherical microparticles. The drug underwent amorphization within the microparticles, with
an encapsulation efficiency greater than 84%. Furthermore, the microparticles exhibited prolonged
release, particularly after the addition of palygorskite. They demonstrated biocompatibility in an
in vitro model, and their release profile was influenced by the proportion of inputs in the formulation.
Therefore, incorporating ETB into this system offers improved stability for the administered product
in the initial tuberculosis pharmacotherapy dose, minimizing its contact with other tuberculostatic
agents in the treatment, as well as reducing its hygroscopicity